Comparative Pharmacology
Head-to-head clinical analysis: BOSUTINIB versus CABOZANTINIB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BOSUTINIB versus CABOZANTINIB.
BOSUTINIB vs CABOZANTINIB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bosutinib is a tyrosine kinase inhibitor that inhibits the BCR-ABL kinase, including many imatinib-resistant mutations, and Src family kinases.
Small molecule tyrosine kinase inhibitor that targets MET, VEGFR2, RET, AXL, KIT, TIE2, FLT3, and TRKB. Inhibits tumor growth, angiogenesis, and metastasis.
400 mg orally once daily with food.
60 mg orally once daily, taken without food (at least 1 hour before or 2 hours after eating).
None Documented
None Documented
Terminal elimination half-life approximately 33 hours (range 22-60 hr) after oral administration, supporting once-daily dosing.
Clinical Note
moderateCabozantinib + Digoxin
"Cabozantinib may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateBosutinib + Digoxin
"The serum concentration of Digoxin can be increased when it is combined with Bosutinib."
Clinical Note
moderateCabozantinib + Digitoxin
"Cabozantinib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateBosutinib + Digitoxin
"Bosutinib may decrease the cardiotoxic activities of Digitoxin."
Terminal elimination half-life is approximately 99 hours (range 68–136 hours) in patients with advanced solid tumors, supporting once-daily dosing.
Primarily fecal (approx. 68% as unchanged drug and metabolites) and renal (approx. 25%, with <0.2% as unchanged drug in urine).
Primarily fecal (approximately 54% of administered dose as unchanged drug and metabolites), with renal excretion accounting for approximately 27% (largely as metabolites). Mean total recovery in feces and urine is about 81%.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor